CYTOF supply chain intelligence for Altamira Therapeutics Ltd.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Altamira Therapeutics Ltd. (CYTOF) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HEQET-THERAPEUTICS | HEQET-THERAPEUTICS | 92% | In July 2023, we announced our first collaboration with a biopharmaceutical company to develop and evaluate our xPhore delivery platform with a specific RNA molecule developed by the client (Heqet Th… |
| UNIVERCELLS | UNIVERCELLS | 92% | This was followed in 2024 by two further collaborations (March: Univercells, mRNA vaccines; December: undisclosed partner, radiopharmaceuticals). |
| BPTH | Bio-Path Holdings, Inc. | 72% | hnologies There are several companies offering commercial- or developmental-stage technologies for delivering RNA payloads to extrahepatic cells. These include Acuitas Therapeutics Inc., Aposense Ltd… |
| BPTH | Bio-Path Holdings, Inc. | 72% | Reciprocal relationship from BPTH graph: Reciprocal relationship from CYTOF graph: hnologies There are several companies offering commercial- or developmental-stage technologies for delivering RNA pa… |
| JNJ | Johnson & Johnson | 72% | hnologies There are several companies offering commercial- or developmental-stage technologies for delivering RNA payloads to extrahepatic cells. These include Acuitas Therapeutics Inc., Aposense Ltd… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from CYTOF graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CYTOF graph: Reciprocal relationship from JNJ gr… |
| RNAZ | TransCode Therapeutics, Inc. | 72% | hnologies There are several companies offering commercial- or developmental-stage technologies for delivering RNA payloads to extrahepatic cells. These include Acuitas Therapeutics Inc., Aposense Ltd… |
| RNAZ | TransCode Therapeutics, Inc. | 72% | Reciprocal relationship from RNAZ graph: Reciprocal relationship from CYTOF graph: hnologies There are several companies offering commercial- or developmental-stage technologies for delivering RNA pa… |
| SNYNF | Sanofi | 72% | ), as well as our early- to late-stage clinical development programs in tinnitus and hearing loss. We started our activities in RNA delivery in 2021 through the acquisition of Trasir Therapeutics Inc… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CYTOF graph: ), as well as our early- to late-stage clinical development programs in tinnitus and hearing loss. We started our a… |
| ACUITAS-THERAPEUTICS-INC-APOSENSE-LTD-BIO-PATH-H | ACUITAS-THERAPEUTICS-INC-APOSENSE-LTD-BIO-PATH-H | 62% | hnologies There are several companies offering commercial- or developmental-stage technologies for delivering RNA payloads to extrahepatic cells. These include Acuitas Therapeutics Inc., Aposense Ltd… |
| ALTAMIRA-MEDICA-AG | ALTAMIRA-MEDICA-AG | 62% | d embedded derivatives separated from the host and measured at fair value with all changes in fair value recognized in profit or loss. The embedded financial derivatives were initially valued by an i… |
| ALTAMIRA-THERAPEUTICS-AG | ALTAMIRA-THERAPEUTICS-AG | 62% | d embedded derivatives separated from the host and measured at fair value with all changes in fair value recognized in profit or loss. The embedded financial derivatives were initially valued by an i… |
| AURIS-MEDICAL-AG | AURIS-MEDICAL-AG | 62% | erm of 12 years; and a percentage share (in the double digits) of sublicensing revenues received by the Company in connection with licensed products. Such regulatory and sales milestones may total up… |
| BIODRONE-THERAPEUTICS-INC-BIORCHESTRA-CO-LTD | BIODRONE-THERAPEUTICS-INC-BIORCHESTRA-CO-LTD | 62% | hnologies There are several companies offering commercial- or developmental-stage technologies for delivering RNA payloads to extrahepatic cells. These include Acuitas Therapeutics Inc., Aposense Ltd… |
| CO-LLC | CO-LLC | 62% | ), as well as our early- to late-stage clinical development programs in tinnitus and hearing loss. We started our activities in RNA delivery in 2021 through the acquisition of Trasir Therapeutics Inc… |
| DISETRONIC-GROUP | DISETRONIC-GROUP | 62% | ), as well as our early- to late-stage clinical development programs in tinnitus and hearing loss. We started our activities in RNA delivery in 2021 through the acquisition of Trasir Therapeutics Inc… |
| ENTOS-PHARMACEUTICALS-ETHRIS-GMBH-GENEVANT-SCIEN | ENTOS-PHARMACEUTICALS-ETHRIS-GMBH-GENEVANT-SCIEN | 62% | hnologies There are several companies offering commercial- or developmental-stage technologies for delivering RNA payloads to extrahepatic cells. These include Acuitas Therapeutics Inc., Aposense Ltd… |
| FIVET-INVESTMENT-MANAGEMENT-LTD | FIVET-INVESTMENT-MANAGEMENT-LTD | 62% | ents made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in… |
| LINCOLN-PARK-CAPITAL-FUND-LLC | LINCOLN-PARK-CAPITAL-FUND-LLC | 62% | ), as well as our early- to late-stage clinical development programs in tinnitus and hearing loss. We started our activities in RNA delivery in 2021 through the acquisition of Trasir Therapeutics Inc… |
| TRASIR-THERAPEUTICS-INC | TRASIR-THERAPEUTICS-INC | 62% | had warrants to purchase up to 16,445,116 of its common shares issued and outstanding (as of December 31, 2023, the Company had warrants to purchase up to 759,167 common shares). The purchase price f… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CYTOF-DEBT-9004 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-01. |
| CYTOF-DEBT | Debt stack $523,920 | 90% | Market cache reports total debt of $523,920. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 |